2022CSH Professor Zhao Weiying: Talk about the present and future of DLBCL, and be grateful to remember every moment of the 17th National Hematology Academic Conference of the Chinese Medical Association

Lymphoma is one of the common malignancies, with complex pathological types, strong heterogeneity, and different
treatment principles.

In recent years, with the deepening of people's understanding of the nature of lymphoma, the survival of patients has improved
.

Diffuse large B-cell lymphoma (DLBCL) is one of the most common subclasses of non-Hodgkin lymphoma (NHL) and has become one
of the malignant tumors with increasing incidence year by year.

On September 23-25, 2022, the 17th National Hematology Academic Conference of the Chinese Medical Association was grandly opened
at the National Exhibition and Convention Center in Shanghai.

The conference was hosted by the Chinese Medical Association and the Hematology Branch of the Chinese Medical Association, hosted by the Shanghai Medical Association, co-organized by Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the First Affiliated Hospital of Soochow University, and the Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, with the theme of "respect, inheritance, collaboration and innovation", specially invited famous experts at home and abroad to talk about the latest progress
in the field of blood diseases.

On this occasion, Professor Zhao Weicheng of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine was invited to interpret the current situation and challenges, clinical treatment difficulties, latest treatment progress and future development in the field of DLBCL for the readers!

DLBL is one of the most common malignant lymphomas in the clinic and has a high incidence, can you please talk about the treatment status and treatment difficulties of DLBCL?

Due to the high incidence of DLBCL, the efficacy needs to be further improved, and it has been concerned
by clinicians in the field of lymphoma.

At this CSH conference, the American Society of Hematology Annual Meeting (ASH)-CSH Joint Forum also discussed the current treatment bottleneck
of DLBCL.

The diagnosis of DLBCL is relatively standardized, but in terms of treatment, treatment-related targets are still being sought at home and abroad
.

Many modern omics studies have made it clearer to show the genomic data of patients, but how to land in the clinic and determine molecular typing in a simple and rapid way is currently a challenge
.

Centers are actively collaborating with industry-university-research to develop a method
that enables patients to obtain molecular classification categories in a relatively short period of time for targeted therapy.

Ruijin Hospital also launched the Guidance-02 study on the basis of Guidance-01, which determined the molecular classification of patients during the treatment of the first course of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), combined with targeted therapy, and proposed a relatively better treatment
.

With the continuous launch of new drugs, the future will focus on the integration of new and old drugs and hematopoietic stem cell transplantation, so that patients with relapse and refractory patients have hope for
a cure.

With the continuous development of precision diagnosis, molecular typing and targeted drugs, the treatment of DLBCL is also advancing, what do you think are the new drugs or new therapies in the field of DLBCL treatment that are worth paying attention to?

At present, clinical attention is paid to small molecule targeted drugs such as BTK inhibitors and epigenetic regulatory drugs such as cedabenamide, and the research and development of new targeted drugs has also received great attention
.

The conference features an innovative R&D pipeline to give clinicians a deeper understanding of emerging targeted medicines available
.

Not only that, immunotherapy-based strategies such as CAR-T therapy, bispecific antibodies, PD-1 targets, or emerging immune checkpoint inhibitors will be promising therapeutic strategies
for DLBCL in the future.

In addition, the drug regulatory policy innovation venue can allow clinicians to get closer to the State Food and Drug Administration, providing a better platform
for patients' innovative treatment plans.

Medical Pulse Communication: Domestic and foreign researchers have been actively exploring DLBCL treatment options and strategies, your team has also been committed to studying DLBCL better curing options, can you please talk about the development of the field of DLBCL treatment in recent years and the prospect of future treatment trends of DLBCL?

In the past, clinically, patients were initially stratified by IPI analysis, then treated with R-CHOP regimens, and transplanted
in subsequent recurrences.

Now, in the case of targeted therapy, cell immunotherapy and transplantation coexistence, IPI typing is still needed, low-risk patients can be cured by R-CHOP regimen treatment, medium- and high-risk patients can use R-CHOP-X treatment regimen, without increasing chemotherapy, and also can use cellular immunotherapy or transplantation as a second-line treatment plan, but the most important thing is how to identify which treatment regimen the patient is suitable for before treatment, therefore, Tailor-made personalized treatment will be the trend
of DLBCL in the future.

Medical Pulse Pass: The first national major scientific research infrastructure has been officially completed in the transformation building of Ruijin Hospital, and your team has also achieved great results in translational medicine, how do you feel about the exchange and mutual assistance between domestic counterparts?

The development of Ruijin Hospital is inseparable from the support of national experts, the construction of the National Translational Medicine Center has been nearly two years, it is precisely because the transformation center has a good platform, giving the wings of scientific research, therefore, clinicians can transform the concerns of patients into scientific concepts
.

In the future, the development of new strategies for targeted therapy based on pathogenesis is the direction
that needs attention.

At the same time, the relationship between tumors and aging has also attracted attention, Academician Chen Zhu specifically mentioned the close relationship between aging and tumors at the conference, to some extent, DLBCL is an age-related disease, and is currently trying to use ChemoFree methods to treat elderly patients who are ultra-old or not suitable for chemotherapy, and have achieved preliminary results, confirming that ChemoFree's methods can make a considerable number of patients cured,
。
In addition, the more important idea of the lymphocyte disease group is to actively cooperate with experts from all over the country to answer the world's problems
with Chinese data.

Medical Pulse Tong: For the grand convening of this conference, your team has made great contributions and made great efforts, many academicians attended the meeting and brought wonderful reports, and at the same time set up a tribute ceremony for the experts of the older generation, for the victory of this conference, can you please share your feelings?

Our team has held many meetings that have left a very deep impression together, but the "17th National Hematology Academic Conference of the Chinese Medical Association" will be engraved in my heart, because this conference not only has the efforts of the team, but also the support of the national peers, and every chairman, speaker and industry-university-research colleagues who support the development of blood have invested a lot of energy
.

The conference has been in preparation for more than a year, and everyone is doing their best to accomplish the cause
.

I firmly believe that the blood conference is the embodiment of the highest academic level of Chinese blood, no matter how much effort is very worthwhile, we should show the fruitful achievements and strong academic ability of Chinese blood experts to everyone, to the world, which is also the original intention and determination
of every colleague of this conference to go through hardships and overcome all difficulties.

Professor Zhao Weiying

• Vice President of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Chief Physician, Professor, Doctoral Supervisor

• Winner of the National Science Foundation for Outstanding Youth

• Jiang Scholar Distinguished Professor, Ministry of Education

• The Ministry of Science and Technology is a leading talent in the 10,000-person plan

• The national candidate of the 100 Million Talents Project is the executive deputy director of the Shanghai Institute of Hematology

• Executive Deputy Director of the Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

• Vice Chairman of the Hematology Branch of the Chinese Medical Association, Leader of the Lymphocyte Disease Group

• Director of the Chinese Society of Pathophysiology

• Secretary General and Standing Committee Member of the Chinese Society of Experimental Hematology

• Vice President of the Anti-Lymphoma Alliance of the Chinese Clinical Oncology Association

• Dedicated to clinical and basic research on lymphocyte malignant diseases, with the newsletter/first author in "CANCER CELL", "NATURE GENETICS", "BLOOD", "MOLECULAR CANCER", "SIGNAL TRANSDUCT TARGET THER", "J HEMATOL ONCOL", "LANCET HAEMATOL", "CLIN CANCER RES" and other international authoritative journals published more than 100 articles, the total impact factor of more than 940 points

• His achievements have won the second prize of the National Science and Technology Progress Award, the first prize of the Ministry of Education's Natural Sciences, the first prize of the Science and Technology Progress Award, the first prize of the Huaxia Medical Science and Technology Award (the first person to complete it), the China Young Women's Science Award and the Shanghai Natural Science Peony Award

• He has won 6 national invention patents, presided over a number of national 863 major projects, the National Natural Science Foundation of China and provincial and ministerial key projects

Poke "Read the original article" and go to the micro-official website to get more meeting information